DrugPatentWatch Database Preview
VIIBRYD Drug Profile
Which patents cover Viibryd, and when can generic versions of Viibryd launch?
Viibryd is a drug marketed by Allergan and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has ninety-two patent family members in thirty-two countries.
The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.
US ANDA Litigation and Generic Entry Outlook for Viibryd
A generic version of VIIBRYD was approved as vilazodone hydrochloride by TEVA PHARMS USA on January 28th, 2020.
Summary for VIIBRYD
| International Patents: | 92 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 68 |
| Clinical Trials: | 16 |
| Patent Applications: | 35 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VIIBRYD |
| Drug Sales Revenues: | Drug sales revenues for VIIBRYD |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIIBRYD |
| DailyMed Link: | VIIBRYD at DailyMed |
Recent Clinical Trials for VIIBRYD
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Forest Laboratories | Phase 1 |
| New York State Psychiatric Institute | Phase 4 |
| Forest Laboratories | Phase 3 |
Recent Litigation for VIIBRYD
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc. | 2015-11-23 |
| Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc. | 2015-03-30 |
| Forest Laboratories LLC v. Accord Healthcare Inc. | 2015-03-27 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Argentum Pharmaceuticals LLC | 2018-01-05 |
Synonyms for VIIBRYD
| 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride |
| 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine hydrochloride |
| 1-[4-(5-cyanoindol-3-yl)butyl]4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride |
| 163521-08-2 |
| 2-Benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1) |
| 2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride |
| 2794AH |
| 4-(2-carbamoyl-1-benzofuran-5-yl)-1-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-ium chloride |
| 5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide hydrochloride |
| 5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide monohydrochloride |
| 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2carboxamide hydrochloride |
| 5-[4-[4-(5-Cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide hydrochloride |
| 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide hydrochloride |
| 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide;hydrochloride |
| 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride |
| 5-[4-[4-(5-Cyanoindol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride |
| 5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide hydrochloride |
| 521V128 |
| A3919 |
| AB0000947 |
| AC-25885 |
| AC1OCFA0 |
| AK161007 |
| AKOS024464039 |
| AN-5344 |
| API0009252 |
| AX8294006 |
| BCP11496 |
| C26H27N5O2.ClH |
| CCG-213313 |
| CHEBI:70705 |
| CHEMBL1615374 |
| CS-0549 |
| D09699 |
| EBD2199528 |
| EMD 68 843 |
| EMD 68843 |
| EMD-68-843 |
| EMD-68843 |
| EMD68843 |
| HY-14261 |
| J-525160 |
| KB-81444 |
| KS-00000SKE |
| LS-34922 |
| MolPort-028-744-909 |
| RL02096 |
| RL02097 |
| RPZBRGFNBNQSOP-UHFFFAOYSA-N |
| s4259 |
| SB 659746A |
| SB-659746-A |
| SB-659746A |
| SB659746-A |
| SB659746A |
| SCHEMBL867358 |
| ST24050347 |
| SW219887-1 |
| U8HTX2GK8J |
| UNII-U8HTX2GK8J |
| Viibryd (TN) |
| Vilazodone (Hydrochloride) |
| Vilazodone HCl |
| Vilazodone hydrochloride |
| Vilazodone hydrochloride (USAN) |
| Vilazodone hydrochloride [USAN] |
| Vilazodone hydrochloride solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material |
| Vilazodone hydrochloride, >=98% (HPLC) |
| vilazodone monohydrochloride |
| Vilazodonei |
Paragraph IV (Patent) Challenges for VIIBRYD
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| VIIBRYD | TABLET;ORAL | vilazodone hydrochloride | 022567 | 2015-01-21 |
US Patents and Regulatory Information for VIIBRYD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | |
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIIBRYD
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-001 | Jan 21, 2011 | Start Trial | Start Trial |
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-002 | Jan 21, 2011 | Start Trial | Start Trial |
| Allergan | VIIBRYD | vilazodone hydrochloride | TABLET;ORAL | 022567-003 | Jan 21, 2011 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIIBRYD
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hungary | 9402806 | Start Trial |
| Hungary | 0400236 | Start Trial |
| Spain | 2330314 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
